#SARSCoV2 mRNA vaccine development enabled by prototype pathogen preparedness
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation. |
SpaceX Starship ‘Lost’ After Reaching Space During Third Test Flight
863314.03.2024, 20:27Neuralink's first human patient can control mouse through thinking, says Elon Musk
441320.02.2024, 15:24A Bronze Age lip-paint from southeastern Iran (photo)
361706.02.2024, 20:24Apple thinks iOS 18 might be the ‘biggest’ iOS update ever
206103.02.2024, 20:06Elon Musk's Neuralink implants brain chip in first human (video)
364930.01.2024, 10:30Nokia smartphone brand will soon disappear: Why has it failed to gain a place in the market?
514618.01.2024, 23:48